81 related articles for article (PubMed ID: 21683711)
1. Restricted occupancy models for neutralization of HIV virions and populations.
Magnus C; Regoes RR
J Theor Biol; 2011 Aug; 283(1):192-202. PubMed ID: 21683711
[TBL] [Abstract][Full Text] [Related]
2. Estimating the stoichiometry of HIV neutralization.
Magnus C; Regoes RR
PLoS Comput Biol; 2010 Mar; 6(3):e1000713. PubMed ID: 20333245
[TBL] [Abstract][Full Text] [Related]
3. The HIV-1 Entry Process: A Stoichiometric View.
Brandenberg OF; Magnus C; Regoes RR; Trkola A
Trends Microbiol; 2015 Dec; 23(12):763-774. PubMed ID: 26541228
[TBL] [Abstract][Full Text] [Related]
4. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
Donners H; Davis D; Willems B; van der Groen G
J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
[TBL] [Abstract][Full Text] [Related]
5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection.
Ciupe SM; De Leenheer P; Kepler TB
J Theor Biol; 2011 May; 277(1):55-66. PubMed ID: 21315731
[TBL] [Abstract][Full Text] [Related]
7. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
[TBL] [Abstract][Full Text] [Related]
8. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
[TBL] [Abstract][Full Text] [Related]
9. Challenges for structure-based HIV vaccine design.
Schief WR; Ban YE; Stamatatos L
Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of animal virus infectivity by antibody.
Reading SA; Dimmock NJ
Arch Virol; 2007; 152(6):1047-59. PubMed ID: 17516034
[TBL] [Abstract][Full Text] [Related]
11. Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization.
Hioe CE; Bastiani L; Hildreth JE; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S247-54. PubMed ID: 9814951
[TBL] [Abstract][Full Text] [Related]
12. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization.
Fortin JF; Cantin R; Bergeron MG; Tremblay MJ
Virology; 2000 Mar; 268(2):493-503. PubMed ID: 10704357
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
[TBL] [Abstract][Full Text] [Related]
14. Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.
Brandenberg OF; Magnus C; Rusert P; Günthard HF; Regoes RR; Trkola A
PLoS Pathog; 2017 May; 13(5):e1006313. PubMed ID: 28472201
[TBL] [Abstract][Full Text] [Related]
15. Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement.
Beck Z; Brown BK; Matyas GR; Polonis VR; Rao M; Alving CR
Virology; 2011 Apr; 412(2):441-7. PubMed ID: 21334707
[TBL] [Abstract][Full Text] [Related]
16. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.
Klasse PJ
Virology; 2007 Dec; 369(2):245-62. PubMed ID: 17825343
[TBL] [Abstract][Full Text] [Related]
17. Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier.
Lorin V; Danckaert A; Porrot F; Schwartz O; Afonso PV; Mouquet H
mBio; 2020 Oct; 11(5):. PubMed ID: 33082263
[TBL] [Abstract][Full Text] [Related]
18. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
[TBL] [Abstract][Full Text] [Related]
19. Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections.
Robinson WE; Mitchell WM
AIDS; 1990; 4 Suppl 1():S151-62. PubMed ID: 2152561
[TBL] [Abstract][Full Text] [Related]
20. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
